April 27, China National Biotec Group Company (CNBG) announced that the new coronavirus inactivated vaccine developed by CNBG Beijing Bioproducts Research Institute was approved for clinical trials by the State Food and Drug Administration, and the clinical trial was officially launched in Henan on April 28.
This is the second novel inactivated coronavirus vaccine approved for clinical use by CNBG.
The inactivated coronavirus vaccine was approved for clinical use by the Wuhan Biological Products Research Institute of China and the Wuhan Institute of Virus Research of the Chinese Academy of Sciences and entered the Phase II clinical trial stage on April 24.
CNBG has completed the construction of a new coronavirus vaccine production plant in Beijing, with an annual production capacity of 100 million doses after mass production, and is equipped to meet the production conditions for mass emergency use and routine vaccination.
Special Report:ย Fighting The New Coronavirus
More on Tech Industry
